{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T17:56:06Z","timestamp":1791741366287,"version":"4.3.4"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.lfs.2021.119744","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:23:07Z","timestamp":1624519387000},"page":"119744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective"],"prefix":"10.1016","volume":"280","author":[{"given":"Yinghan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Wi","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil Kumar","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goh Bey","family":"Hing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudi","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"MacLoughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimar","family":"L\u00f6benberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Chellappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2021.119744_bb0005","series-title":"Forum of International Respiratory Societies The Global Impact of Respiratory Disease","year":"2017"},{"key":"10.1016\/j.lfs.2021.119744_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3947\/ic.2014.46.2.67","article-title":"Etiology and clinical outcomes of acute respiratory virus infection in hospitalized adults","volume":"46","author":"Seo","year":"2014","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.lfs.2021.119744_bb0015","first-page":"85","article-title":"Respiratory viruses","author":"Weston","year":"2019","journal-title":"Encycl. Microbiol."},{"key":"10.1016\/j.lfs.2021.119744_bb0020","series-title":"Viral Respiratory Infections. Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases","first-page":"284","author":"van Doorn","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0025","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.immuni.2020.05.004","article-title":"Respiratory virus infections: understanding COVID-19","volume":"52","author":"Subbarao","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.lfs.2021.119744_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-based vaccines against respiratory viruses","volume":"10","author":"Al-Halifa","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1055\/s-0031-1283289","article-title":"Progress in respiratory virus vaccine development","volume":"32","author":"Schmidt","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/wnan.45","article-title":"Nanoparticle vaccines against respiratory viruses","volume":"1","author":"Adair","year":"2009","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.lfs.2021.119744_bb0045","article-title":"Vaccines Through Centuries: Major Cornerstones of Global Health. Frontiers in Public Health","volume":"3","author":"Hajj Hussein","year":"2015"},{"key":"10.1016\/j.lfs.2021.119744_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.lfs.2021.119744_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines4020012","article-title":"Recent advances in subunit vaccine carriers","volume":"4","author":"Vartak","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.lfs.2021.119744_bb0060","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/21645515.2017.1423153","article-title":"Influenza vaccines: evaluation of the safety profile","volume":"14","author":"Trombetta","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.lfs.2021.119744_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/polym10010031","article-title":"Polymer-based nanomaterials and applications for vaccines and drugs","volume":"10","author":"Han","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.lfs.2021.119744_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080375","article-title":"Mucosal vaccination via the respiratory tract","volume":"11","author":"Hellfritzsch","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2021.119744_bb0075","series-title":"Hurdles in Vaccine Development Against Respiratory Syncytial Virus. The Burden of Respiratory Syncytial Virus Infection in the Young","author":"Shafique","year":"2019"},{"key":"10.1016\/j.lfs.2021.119744_bb0080","series-title":"Epidemiology of Respiratory Infections. Pediatric Respiratory Diseases","first-page":"263","author":"Carvajal","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0085","article-title":"Pathogenesis of viral respiratory infection. Respiratory disease and infection - a new insight","author":"Ma","year":"2013","journal-title":"INTECH"},{"key":"10.1016\/j.lfs.2021.119744_bb0090","series-title":"Pathogenesis of Virus Infections. Fenner and White\u2019s Medical Virology","first-page":"77","author":"Burrell","year":"2017"},{"key":"10.1016\/j.lfs.2021.119744_bb0095","series-title":"Human Respiratory Viruses?. Reference Module in Biomedical Sciences","author":"Crowe","year":"2014"},{"key":"10.1016\/j.lfs.2021.119744_bb0100","series-title":"Respiratory Viral Pathogens. Reference Module in Biomedical Sciences","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.chom.2016.01.001","article-title":"The interaction between respiratory pathogens and mucus","volume":"19","author":"Zanin","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2021.119744_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1128\/CMR.00014-10","article-title":"The airway epithelium: soldier in the fight against respiratory viruses","volume":"24","author":"Vareille","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5339\/gcsp.2015.2","article-title":"Inhaled nano- and microparticles for drug delivery","volume":"2015","author":"El-Sherbiny","year":"2015","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"10.1016\/j.lfs.2021.119744_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2014.05.014","article-title":"Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery","volume":"75","author":"de Souza","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/ejnm-2014-0019","article-title":"Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics","volume":"6","author":"Murgia","year":"2014","journal-title":"Eur. J. Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119744_bb0130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2011.12.015","article-title":"Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge-an ex vivo and in silico approach","volume":"159","author":"Kirch","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119744_bb0135","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028241","article-title":"Cilia and mucociliary clearance","volume":"9","author":"Bustamante-Marin","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.lfs.2021.119744_bb0140","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1183\/13993003.00120-2015","article-title":"Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions","volume":"48","author":"Janssen","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lfs.2021.119744_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/09059180.05.00009501","article-title":"Lung defences: an overview","volume":"14","author":"Nicod","year":"2005","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fimmu.2018.01521","article-title":"Respiratory mononuclear phagocytes in human influenza a virus infection: their role in immune protection and as targets of the virus","volume":"9","author":"Vangeti","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0155","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3389\/fimmu.2018.01777","article-title":"Alveolar macrophages in the resolution of inflammation, tissue repair, and tolerance to infection","volume":"9","author":"Allard","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0160","article-title":"Alveolar macrophage phagocytosis and bacteria clearance in mice","volume":"2019","author":"Nagre","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.lfs.2021.119744_bb0165","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/imcb.12235","article-title":"Airway macrophages as the guardians of tissue repair in the lung","volume":"97","author":"Puttur","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.lfs.2021.119744_bb0170","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10354-016-0461-2","article-title":"Wege des Viruseintritts: am Beispiel der Erk\u00e4ltungsviren","volume":"166","author":"Blaas","year":"2016","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.lfs.2021.119744_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrmicro817","article-title":"Virus entry: molecular mechanisms and biomedical applications","volume":"2","author":"Dimitrov","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.lfs.2021.119744_bb0180","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3390\/v7062747","article-title":"Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis","volume":"7","author":"Boulant","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2021.119744_bb0185","first-page":"1289","article-title":"Virus entry at a glance","volume":"126","author":"Yamauchi","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0190","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-020-01908-5","article-title":"Recent advancement in nanotechnology-based drug delivery system against viral infections","volume":"22","author":"Pradhan","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.lfs.2021.119744_bb0195","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016972","article-title":"Endocytosis of viruses and bacteria","volume":"6","author":"Cossart","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.lfs.2021.119744_bb0200","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1007\/s00705-017-3497-8","article-title":"A comparative review of viral entry and attachment during large and giant dsDNA virus infections","volume":"162","author":"Sobhy","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.lfs.2021.119744_bb0205","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jmb.2018.03.034","article-title":"Virus entry: looking back and moving forward","volume":"430","author":"Helenius","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.lfs.2021.119744_bb0210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1743-422X-10-177","article-title":"Multiscale perspectives of virus entry via endocytosis","volume":"10","author":"Barrow","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.lfs.2021.119744_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tim.2018.06.008","article-title":"Exploitation of cytoskeletal networks during early viral infection","volume":"27","author":"Walsh","year":"2019","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.lfs.2021.119744_bb0220","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12250-019-00178-1","article-title":"Endosomes and microtubles are required for productive infection in aquareovirus","volume":"35","author":"Zhang","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.lfs.2021.119744_bb0225","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.7150\/ijbs.45498","article-title":"Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0230","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000312912","article-title":"A dilemma for viruses and giant viruses: which endocytic pathway to use to enter cells?","volume":"53","author":"Ghigo","year":"2010","journal-title":"Intervirology"},{"key":"10.1016\/j.lfs.2021.119744_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2013\/306595","article-title":"Molecular signaling and cellular pathways for virus entry","volume":"2013","author":"Chi","year":"2013","journal-title":"ISRN Virol."},{"key":"10.1016\/j.lfs.2021.119744_bb0240","series-title":"Encyclopedia of the Neurological Sciences","first-page":"659","article-title":"Viral vbaccines and antiviral therapy","author":"Tselis","year":"2014"},{"key":"10.1016\/j.lfs.2021.119744_bb0245","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2217\/fvl.15.53","article-title":"Addressing viral resistance through vaccines","volume":"10","author":"Laughlin","year":"2015","journal-title":"Futur. Virol."},{"key":"10.1016\/j.lfs.2021.119744_bb0250","series-title":"Respiratory Virus Vaccines. Mucosal Immunology","first-page":"1129","volume":"vol. 1\u20132","author":"Broadbent","year":"2015"},{"key":"10.1016\/j.lfs.2021.119744_bb0255","series-title":"Antiviral Vaccines: Challenges and Advances. The Vaccine Book","first-page":"283","author":"Ellebedy","year":"2016"},{"key":"10.1016\/j.lfs.2021.119744_bb0260","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0265","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1099\/jgv.0.000959","article-title":"ICTV virus taxonomy profile: pneumoviridae","volume":"98","author":"Rima","year":"2017","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.lfs.2021.119744_bb0270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s40506-018-0163-y","article-title":"Transmission and control of respiratory viral infections in the healthcare setting","volume":"10","author":"Bonveh\u00ed","year":"2018","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004016","article-title":"An overview of respiratory syncytial virus","volume":"10","author":"Meng","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.lfs.2021.119744_bb0280","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10405-019-0252-8","article-title":"Respiratory syncytial virus infections","volume":"16","author":"Wetzke","year":"2019","journal-title":"Pneumologe"},{"key":"10.1016\/j.lfs.2021.119744_bb0285","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1542\/pir.35.12.519","article-title":"Respiratory syncytial virus infection and bronchiolitis","volume":"35","author":"Piedimonte","year":"2014","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.01.006","article-title":"Treatment of respiratory virus infections","volume":"70","author":"Abed","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.lfs.2021.119744_bb0295","article-title":"Respiratory syncytial virus: diagnosis, prevention and management","volume":"6","author":"Barr","year":"2019","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0300","first-page":"6","article-title":"Respiratory illness associated with emergent human adenovirus genome type 7d, New Jersey, 2016\u20132017","author":"Killerby","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0305","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3201\/eid2206.151898","article-title":"Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013\u20132014","volume":"22","author":"Kendall Scott","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0310","series-title":"Adenoviruses","author":"Usman","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0315","doi-asserted-by":"crossref","DOI":"10.21037\/jtd.2018.03.168","article-title":"Vaccine development for human mastadenovirus","volume":"10","author":"Chen","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0320","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1055\/s-0036-1584798","article-title":"Parainfluenza virus infection","volume":"37","author":"Branche","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0325","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.coviro.2012.02.001","article-title":"Pathogenesis of acute respiratory illness caused by human parainfluenza viruses","volume":"2","author":"Schomacker","year":"2012","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.lfs.2021.119744_bb0330","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1086\/425981","article-title":"Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children","volume":"190","author":"Belshe","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0335","series-title":"Influenza","author":"Boktor","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0340","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0345","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","article-title":"Influenza virus-related critical illness: pathophysiology and epidemiology","volume":"23","author":"Kalil","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.lfs.2021.119744_bb0350","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-018-0340-z","article-title":"Current and future influenza vaccines","volume":"25","author":"Yamayoshi","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0355","doi-asserted-by":"crossref","first-page":"110298","DOI":"10.1016\/j.mehy.2020.110298","article-title":"Advanced drug delivery systems can assist in managing influenza virus infection: a hypothesis","volume":"144","author":"Chan","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.lfs.2021.119744_bb0360","first-page":"372","article-title":"Influenza vaccines","volume":"12","author":"Senthur Nambi","year":"2010","journal-title":"Indian J. Pract. Pediatr."},{"key":"10.1016\/j.lfs.2021.119744_bb0365","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0370","series-title":"Coronaviruses: Methods and Protocols","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"vol. 1282","author":"Fehr","year":"2015"},{"key":"10.1016\/j.lfs.2021.119744_bb0375","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/path.4454","article-title":"Molecular pathology of emerging coronavirus infections","volume":"235","author":"Gralinski","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.lfs.2021.119744_bb0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.15698\/cst2020.04.216","article-title":"Coronavirus infections: epidemiological, clinical and immunological features and hypotheses","volume":"4","author":"Raoult","year":"2020","journal-title":"Cell Stress"},{"key":"10.1016\/j.lfs.2021.119744_bb0385","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","article-title":"Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus","volume":"69","author":"Weiss","year":"2005","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0390","series-title":"Severe Acute Respiratory Syndrome","author":"Hodgens","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00028-20","article-title":"Coronavirus disease 2019\u2013COVID-19","volume":"33","author":"Dhama","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.lfs.2021.119744_bb0400","first-page":"2020","article-title":"(COVID-19): Evaluation and Prevention","volume":"2020","author":"Ouassou","year":"2019","journal-title":"J Immunol Res"},{"key":"10.1016\/j.lfs.2021.119744_bb0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.vacune.2020.10.009","article-title":"A review on promising vaccine development progress for COVID-19 disease","volume":"21","author":"Belete","year":"2020","journal-title":"Vacunas (English Edition)"},{"key":"10.1016\/j.lfs.2021.119744_bb0415","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.micinf.2020.05.001","article-title":"Current development of COVID-19 diagnostics, vaccines and therapeutics","volume":"22","author":"Zhang","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.lfs.2021.119744_bb0420","doi-asserted-by":"crossref","DOI":"10.1021\/acscentsci.1c00120","article-title":"A comprehensive review of the global efforts on COVID-19 vaccine development","author":"Li","year":"2021","journal-title":"ACS Central Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0425","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.lfs.2021.119744_bb0430","first-page":"1","article-title":"Will SARS-CoV-2 variants of concern affect the promise of vaccines?","author":"Gupta","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0435","first-page":"1","article-title":"Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies","author":"Bian","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2021.119744_bb0440","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"KRW","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2021.119744_bb0445","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","volume":"29","author":"Shen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.lfs.2021.119744_bb0450","first-page":"593","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119744_bb0455","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119744_bb0460","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2021.119744_bb0465","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0470","first-page":"35","article-title":"Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants","author":"Sah","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lfs.2021.119744_bb0475","series-title":"Nanotechnologies Applied in Biomedicines\u2019 Vaccine. Micro and Nanotechnologies for Biotechnology","year":"2016"},{"key":"10.1016\/j.lfs.2021.119744_bb0480","first-page":"227","article-title":"Nanotechnology and vaccine development","volume":"9","author":"Kim","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0485","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trsl.2011.12.009","article-title":"Translational research in infectious disease: current paradigms and challenges ahead","volume":"159","author":"Fontana","year":"2012","journal-title":"Transl. Res."},{"key":"10.1016\/j.lfs.2021.119744_bb0490","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jconrel.2015.09.047","article-title":"Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation","volume":"219","author":"Renukaradhya","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119744_bb0495","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14760584.2018.1541408","article-title":"Universal influenza vaccines: from viruses to nanoparticles","volume":"17","author":"Wang","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.lfs.2021.119744_bb0500","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/cei.13285","article-title":"Mucosal vaccines and technology","volume":"196","author":"Miquel-Clop\u00e9s","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0505","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/jps.23220","article-title":"Immunogenicity and protection of oral influenza vaccines formulated into microparticles","volume":"101","author":"Shastri","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0510","series-title":"Nanoparticle-based Vaccines: Opportunities and Limitations. Opportunities and Limitations. Nanopharmaceuticals: Volume 1: Expectations and Realities of Multifunctional Drug Delivery Systems","first-page":"135","author":"Diaz-Ar\u00e9valo","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0515","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/2211738507666191024162042","article-title":"Nanoparticles and vaccine development","volume":"8","author":"Kheirollahpour","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119744_bb0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1039\/C7MD00158D","article-title":"Applications and perspectives of nanomaterials in novel vaccine development","volume":"9","author":"Shen","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.lfs.2021.119744_bb0525","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.lfs.2021.119744_bb0530","article-title":"Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines","volume":"0","author":"Swingle","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0535","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1039\/C5TB00618J","article-title":"The potential of nanoparticles for the immunization against viral infections","volume":"3","author":"Sokolova","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.lfs.2021.119744_bb0540","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1039\/C9NR08958F","article-title":"Nanoparticle formulated vaccines: opportunities and challenges","volume":"12","author":"Lung","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.lfs.2021.119744_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21249695","article-title":"The impact of nanoparticles on innate immune activation by live bacteria","volume":"21","author":"Swartzwelter","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0550","first-page":"4","article-title":"Vaccine delivery using nanoparticles","author":"Gregory","year":"2013","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.lfs.2021.119744_bb0555","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2021.119744_bb0560","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4155\/fmc-2020-0206","article-title":"Sugar-based nanoparticles for respiratory diseases: a new paradigm in the nanoworld","volume":"12","author":"Chan","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.lfs.2021.119744_bb0565","doi-asserted-by":"crossref","first-page":"2001812","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.lfs.2021.119744_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/v9070186","article-title":"Targeting pattern recognition receptors (PRR) for vaccine adjuvantation: from synthetic PRR agonists to the potential of defective interfering particles of viruses","volume":"9","author":"Vasou","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2021.119744_bb0575","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/nnm-2021-0056","article-title":"Applications and practice of advanced drug delivery systems for targeting Toll-like receptors in pulmonary diseases","volume":"16","author":"Chan","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119744_bb0580","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3934\/biophy.2020023","article-title":"Nanoparticle-based delivery platforms for mRNA vaccine development","volume":"7","author":"Okay","year":"2020","journal-title":"AIMS Biophys."},{"key":"10.1016\/j.lfs.2021.119744_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zielinska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.lfs.2021.119744_bb0590","first-page":"1","article-title":"Nanotechnology-based antiviral therapeutics","author":"Chakravarty","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.lfs.2021.119744_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118731","article-title":"Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines","volume":"572","author":"Jin","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.lfs.2021.119744_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/ma12152445","article-title":"Use of biopolymers in mucosally-administered vaccinations for respiratory disease","volume":"12","author":"Dedloff","year":"2019","journal-title":"Materials"},{"key":"10.1016\/j.lfs.2021.119744_bb0605","doi-asserted-by":"crossref","first-page":"14730","DOI":"10.1038\/s41598-018-32994-y","article-title":"Multivalent and multifunctional polysaccharide-based particles for controlled receptor recognition","volume":"8","author":"Duan","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119744_bb0610","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4155\/tde-2020-0033","article-title":"Synthetic polymers from renewable feedstocks: an alternative to fossil-based materials in biomedical applications","volume":"11","author":"Bansal","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.lfs.2021.119744_bb0615","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7048-C1-011","article-title":"Biodegradable synthetic polymers and their application in advanced drug delivery systems (DDS)","volume":"09","author":"Jerbic","year":"2018","journal-title":"J. Chem. Eng. Process. Technol."},{"key":"10.1016\/j.lfs.2021.119744_bb0620","doi-asserted-by":"crossref","DOI":"10.1088\/2632-959X\/ab8075","article-title":"Organic and inorganic nanoparticle vaccines for prevention of infectious diseases","volume":"1","author":"Poon","year":"2020","journal-title":"Nano Express"},{"key":"10.1016\/j.lfs.2021.119744_bb0625","first-page":"8","article-title":"Chitosan nanoparticle based mucosal vaccines delivered against infectious diseases of poultry and pigs","author":"Renu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2021.119744_bb0630","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/17425247.2012.697455","article-title":"Chitosan-based delivery systems for mucosal vaccines","volume":"9","author":"Jabbal-Gill","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.lfs.2021.119744_bb0635","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5582\/ddt.2015.01025","article-title":"Polysaccharides: candidates of promising vaccine adjuvants","volume":"9","author":"Li","year":"2015","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.lfs.2021.119744_bb0640","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/polym10030267","article-title":"Chitosan and its derivatives for application in mucoadhesive drug delivery systems","volume":"10","author":"Ways T","year":"2018","journal-title":"Polymers"},{"key":"10.1016\/j.lfs.2021.119744_bb0645","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1016\/j.vaccine.2019.06.003","article-title":"Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice","volume":"37","author":"Muralidharan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119744_bb0650","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1208\/s12249-013-0058-7","article-title":"Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine","volume":"15","author":"Sawaengsak","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.lfs.2021.119744_bb0655","first-page":"76","article-title":"Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model","author":"Sadati","year":"2018","journal-title":"Pathog. Dis."},{"key":"10.1016\/j.lfs.2021.119744_bb0660","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nm1174","article-title":"Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene","volume":"11","author":"Zhang","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0665","series-title":"Polysaccharide Carriers for Drug Delivery","first-page":"1","article-title":"Natural polysaccharides: structural features and properties","author":"Yadav","year":"2019"},{"key":"10.1016\/j.lfs.2021.119744_bb0670","first-page":"104","article-title":"AIEgen quantitatively monitoring the release of Ca2 during swelling and degradation process in alginate hydrogels","author":"Tavakoli","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.lfs.2021.119744_bb0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph13110335","article-title":"Alginate nanoformulation: influence of process and selected variables","volume":"13","author":"Choukaife","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.lfs.2021.119744_bb0680","first-page":"14","article-title":"Alginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting","author":"Abasalizadeh","year":"2020","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.lfs.2021.119744_bb0685","first-page":"5","article-title":"Polysaccharide-based controlled release systems for therapeutics delivery and tissue engineering: from bench to bedside","author":"Miao","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0690","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0250-474X.119829","article-title":"Alginate nanoparticles as a promising adjuvant and vaccine delivery system","volume":"75","author":"Sarei","year":"2013","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0695","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejpb.2012.04.007","article-title":"Chitosan-based drug delivery systems","volume":"81","author":"Bernkop-Schn\u00fcrch","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.lfs.2021.119744_bb0700","first-page":"216","article-title":"Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization","volume":"14","author":"Mosafer","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0705","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.24","article-title":"Self-replicating replicon-rna delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo","volume":"3","author":"McCullough","year":"2014","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"10.1016\/j.lfs.2021.119744_bb0710","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jiec.2019.04.044","article-title":"Biodegradable polymers for modern vaccine development","volume":"77","author":"Bose","year":"2019","journal-title":"J. Ind. Eng. Chem."},{"key":"10.1016\/j.lfs.2021.119744_bb0715","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119744_bb0720","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.lfs.2021.119744_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010204","article-title":"Exploiting PLGA-based biocompatible nanoparticles for next-generation tolerogenic vaccines against autoimmune disease","volume":"20","author":"Cappellano","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0730","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.2217\/nnm.14.156","article-title":"Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery","volume":"9","author":"Pavot","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119744_bb0735","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/21645515.2015.1117714","article-title":"PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity","volume":"12","author":"Silva","year":"2016","journal-title":"Hum. Vacci. Immunother."},{"key":"10.1016\/j.lfs.2021.119744_bb0740","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2016.12.039","article-title":"Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs","volume":"247","author":"Dhakal","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2021.119744_bb0745","first-page":"11","article-title":"Entrapment of H1N1 influenza virus derived conserved peptides in PLGA nanoparticles enhances T cell response and vaccine efficacy in pigs","author":"Hiremath","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lfs.2021.119744_bb0750","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.nano.2012.11.001","article-title":"Development of a nanoparticle-based influenza vaccine using the PRINT\u00ae technology","volume":"9","author":"Galloway","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.lfs.2021.119744_bb0755","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.lfs.2021.119744_bb0760","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nnano.2015.330","article-title":"Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers","volume":"11","author":"Sch\u00f6ttler","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2021.119744_bb0765","article-title":"Recent applications of polyethylene glycols (PEGs) and PEG derivatives","author":"Daniela","year":"2014","journal-title":"Mod. Chem. Appl."},{"key":"10.1016\/j.lfs.2021.119744_bb0770","first-page":"28","article-title":"Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol","author":"Pasut","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.lfs.2021.119744_bb0775","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.biomaterials.2017.05.018","article-title":"PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8 T cell responses","volume":"137","author":"Sekiya","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119744_bb0780","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.vaccine.2015.04.094","article-title":"Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group a polysaccharide conjugate vaccine","volume":"33","author":"Zhang","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119744_bb0785","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/mp300190g","article-title":"Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration","volume":"9","author":"Zhan","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2021.119744_bb0790","series-title":"mRNA Vaccines Against COVID-19: Pfizer-BioNTech COVID-19 Vaccine BNT162b2: Prepared by the Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines","year":"2020"},{"key":"10.1016\/j.lfs.2021.119744_bb0795","article-title":"Maintaining safety with SARS-CoV-2 vaccines","author":"Castells","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2021.119744_bb0800","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.bja.2020.12.020","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","volume":"126","author":"Garvey","year":"2021","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.lfs.2021.119744_bb0805","doi-asserted-by":"crossref","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","author":"Sellaturay","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.lfs.2021.119744_bb0810","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3389\/fphar.2018.01397","article-title":"Editorial: advances and challenges in nanomedicine","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2021.119744_bb0815","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.rvsc.2014.03.002","article-title":"Intranasal delivery of nanoparticles encapsulating BPI3V proteins induces an early humoral immune response in mice","volume":"96","author":"Mansoor","year":"2014","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.lfs.2021.119744_bb0820","first-page":"8","article-title":"Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calf","author":"McGill","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2021.119744_bb0825","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.vaccine.2018.02.072","article-title":"Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: preparation and immunogenicity in a mouse model","volume":"36","author":"Dabaghian","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.lfs.2021.119744_bb0830","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1021\/acsbiomaterials.0c01496","article-title":"Prolonged codelivery of hemagglutinin and a TLR7\/8 agonist in a supramolecular polymer-nanoparticle hydrogel enhances potency and breadth of influenza vaccination","volume":"7","author":"Roth","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.lfs.2021.119744_bb0835","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.biomaterials.2018.08.036","article-title":"Virus-mimetic polymer nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine","volume":"183","author":"Lee","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.lfs.2021.119744_bb0840","first-page":"118","article-title":"Intranasal vaccination with influenza HA\/GO-PEI nanoparticles provides immune protection against homo-and heterologous strains","author":"Dong","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2021.119744_bb0845","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2021.119744_bb0850","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/acsbiomaterials.5b00477","article-title":"Combination nanovaccine demonstrates synergistic enhancement in efficacy against influenza","volume":"2","author":"Ross","year":"2016","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.lfs.2021.119744_bb0855","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.micpath.2017.12.011","article-title":"Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: dry powder formulation for nasal immunization in rabbits","volume":"115","author":"Dehghan","year":"2018","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.lfs.2021.119744_bb0860","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.vetmic.2017.01.020","article-title":"Mucosal vaccination of conserved sM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate\/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes","volume":"201","author":"Chowdhury","year":"2017","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.lfs.2021.119744_bb0865","first-page":"29","article-title":"Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against middle east respiratory syndrome Coronavirus","author":"LCW","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.lfs.2021.119744_bb0870","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.bioconjchem.6b00370","article-title":"Thermoresponsive polymer nanoparticles Co-deliver RSV F trimers with a TLR-7\/8 adjuvant","volume":"27","author":"Francica","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.lfs.2021.119744_bb0875","article-title":"Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine","author":"Lam","year":"2021","journal-title":"BioRxiv"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052100730X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052100730X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:51:22Z","timestamp":1758401482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052100730X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":174,"alternative-id":["S002432052100730X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119744","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"119744"}}